Rheumatoid Arthritis Drugs

Rheumatoid Arthritis Drugs Market Outlook

The global Rheumatoid Arthritis Drugs market is projected to reach approximately USD 67 billion by 2035, expanding at a remarkable compound annual growth rate (CAGR) of around 7.5% from 2025 to 2035. The growth of this market can be attributed to the increasing prevalence of rheumatoid arthritis (RA) among the global population, coupled with the rising demand for effective treatment options and advancements in drug development. Factors such as aging demographics and lifestyle changes leading to increased stress levels are contributing to a rise in autoimmune disorders like RA. Furthermore, the growing awareness regarding the disease and its management, improved healthcare infrastructure, and the introduction of innovative therapies are expected to stimulate market growth significantly. Additionally, the rise of biologic drugs and personalized medicine has opened up new avenues for treating this complex disease, thus providing further impetus to market expansion.

Growth Factor of the Market

One of the most significant growth factors for the Rheumatoid Arthritis Drugs market is the increasing incidence of rheumatoid arthritis globally. With millions of people affected by RA, there is a pressing need for effective therapeutic solutions that can manage symptoms and improve the quality of life for patients. Additionally, advancements in biopharmaceutical technologies have led to the development of innovative treatment options, particularly biologics and targeted therapies, which have shown promising results in clinical trials. These new drugs not only provide better efficacy but also have fewer side effects compared to traditional therapies. Moreover, the growing emphasis on early diagnosis and prompt treatment initiation is expected to spur market demand, as timely intervention can significantly alter disease progression. Additionally, ongoing research and clinical trials aiming to discover novel drug formulations are anticipated to further enrich the therapeutic landscape, thus driving the market forward.

Key Highlights of the Market

• Increasing prevalence of rheumatoid arthritis driving demand for effective treatments.
• Advancements in drug development technologies leading to innovative therapies.
• Growing emphasis on early diagnosis and treatment initiation.
• Strong pipeline of drugs undergoing clinical trials and development.
• Rising awareness regarding rheumatoid arthritis management among healthcare providers and patients.

By Drug Type

Nonsteroidal Anti-Inflammatory Drugs:

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) are commonly prescribed for managing the pain and inflammation associated with rheumatoid arthritis. These medications work by inhibiting enzymes known as cyclooxygenases, which play a crucial role in the inflammatory process. NSAIDs, such as ibuprofen and naproxen, are often favored due to their availability and effectiveness in alleviating symptoms. They are typically used as first-line treatment options and are often combined with other medications to enhance efficacy. However, long-term use of NSAIDs may lead to gastrointestinal issues, which necessitates careful monitoring by healthcare professionals. As a result, while NSAIDs remain a staple in RA management, there is an ongoing need for safer alternatives that provide similar pain relief without adverse side effects.

Corticosteroids:

Corticosteroids, including drugs such as prednisone, are anti-inflammatory medications that play a vital role in the treatment of rheumatoid arthritis. These synthetic drugs mimic the effects of hormones produced by the adrenal glands and are used to reduce inflammation and suppress the immune response. Corticosteroids can quickly alleviate symptoms, making them useful for acute flare-ups of RA. However, due to potential side effects, including weight gain, osteoporosis, and increased risk of infections with long-term use, healthcare providers often prescribe them for short durations or in low doses. The corticosteroid market segment is expected to witness steady demand, particularly among patients who struggle with severe disease manifestations and require rapid symptom control.

Disease-Modifying Antirheumatic Drugs:

Disease-Modifying Antirheumatic Drugs (DMARDs) represent a cornerstone in the pharmacological management of rheumatoid arthritis. These medications are distinct as they not only alleviate pain and inflammation but also slow disease progression and prevent joint damage. Traditional DMARDs, such as methotrexate and sulfasalazine, have been widely used for years and remain effective in managing RA symptoms. Moreover, newer biologic DMARDs, including TNF inhibitors and IL-6 inhibitors, have emerged, demonstrating superior efficacy in controlling disease activity. The DMARD segment is expected to witness substantial growth, primarily driven by the increasing adoption of biologic therapies and the rising number of patients diagnosed with rheumatoid arthritis.

Biologics:

Biologics are a class of drugs derived from living organisms and are designed to target specific components of the immune system that contribute to rheumatoid arthritis. These therapies, including agents like adalimumab and etanercept, have revolutionized the treatment landscape for RA due to their ability to significantly improve patient outcomes. Biologics are typically prescribed for patients who have not responded adequately to traditional DMARDs, providing an effective alternative for severe cases. However, the high cost associated with biologic therapies can be a barrier to access for many patients. Nevertheless, the biologics segment is projected to experience rapid growth, driven by increasing awareness among healthcare providers and patients regarding the benefits of targeted therapies.

Janus Kinase Inhibitors:

Janus Kinase Inhibitors (JAK inhibitors) represent a newer class of oral medications that have emerged as a promising option for managing rheumatoid arthritis. JAK inhibitors, such as tofacitinib and baricitinib, work by inhibiting specific enzymes involved in the inflammatory pathways of the immune system, thereby reducing symptoms and improving overall function. Their oral administration offers a convenient alternative to injections, which is particularly appealing to patients. With the continued development of JAK inhibitors and ongoing research into their long-term safety and efficacy, this segment is expected to see significant growth in the coming years as more patients seek effective and user-friendly treatment options for RA.

By Route of Administration

Oral:

Oral administration of rheumatoid arthritis drugs is one of the most common methods employed, ensuring ease of use and patient compliance. Medications such as NSAIDs, DMARDs, and JAK inhibitors are often available in pill form, allowing patients to take their medication conveniently at home. This route of administration is particularly advantageous for patients who may have difficulty with injections or infusions. Moreover, oral therapies can be integrated into a daily routine, thereby enhancing adherence to treatment plans. However, the bioavailability of oral medications can vary, and some drugs may require the presence of food to optimize absorption, making patient education crucial in this regard. As a result, the oral segment is a significant contributor to the overall market, driven by the demand for accessible and user-friendly treatment options.

Parenteral:

Parenteral administration involves delivering rheumatoid arthritis medications through injections or infusions, which is often required for biologics and certain DMARDs. This route allows for rapid absorption of the drug into the bloodstream and is particularly beneficial for patients with severe symptoms who need immediate relief. While parenteral administration can be more effective for some medications, it may present challenges for patients, including discomfort associated with injections and the need for healthcare professionals to administer certain treatments in clinical settings. Despite these challenges, the parenteral segment remains essential to RA management, particularly as advanced biologics continue to gain traction and healthcare providers seek optimal outcomes for their patients. The growth of this segment is supported by an increasing number of patients seeking biologic treatments and the growing availability of self-injection options.

Topical:

Topical administration of rheumatoid arthritis drugs consists of applying medications directly to the skin over affected joints. Topical NSAIDs, such as diclofenac gel, are commonly used to manage localized pain and inflammation without the systemic effects associated with oral medications. This route can provide targeted relief for patients experiencing joint pain without the need for injections or oral dosing. While topical treatments are generally well tolerated and associated with fewer side effects, their efficacy may be limited for more extensive disease involvement. Nevertheless, the topical segment is expected to see steady growth, driven by increasing patient preference for localized treatment options and ongoing development of innovative topical formulations.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies serve as a significant distribution channel for rheumatoid arthritis drugs, particularly for patients requiring inpatient care and specialized treatment plans. Patients often receive medications through hospital pharmacies during their hospital stay, especially when initiating biologic therapies or requiring close monitoring of treatment side effects. Hospital pharmacists play a critical role in ensuring appropriate medication management, patient education, and adherence to treatment protocols. As the number of hospitals and healthcare facilities expands globally, the contribution of hospital pharmacies to the overall market is expected to grow. Moreover, initiatives aimed at enhancing patient outcomes and reducing readmissions through effective medication management are likely to further bolster the role of hospital pharmacies in the rheumatoid arthritis drugs market.

Retail Pharmacies:

Retail pharmacies represent a vital distribution channel for rheumatoid arthritis medications, providing easy access for patients seeking prescription refills and over-the-counter options. These pharmacies cater to the needs of outpatient populations, offering a broad range of medications, including NSAIDs, DMARDs, and topical treatments. The convenience of retail pharmacies plays a significant role in patient adherence to treatment plans, as patients can obtain their medications close to home. Moreover, with the rising trend of chronic disease management and the growing prevalence of rheumatoid arthritis, retail pharmacies are increasingly focusing on patient education and support services. This segment is expected to witness steady growth as more patients seek convenient and accessible ways to manage their condition.

Online Pharmacies:

Online pharmacies have emerged as a significant distribution channel, particularly in the wake of the COVID-19 pandemic, which accelerated the shift toward digital healthcare solutions. These platforms offer patients the convenience of ordering rheumatoid arthritis medications from the comfort of their homes, often with competitive pricing and home delivery options. Online pharmacies can provide access to a wider range of medications, including those that may not be readily available at local retail pharmacies. Additionally, the enhanced focus on telemedicine and remote patient monitoring is expected to drive growth in this channel as patients seek to manage their conditions with minimal disruption to their daily lives. However, the online pharmacy segment also faces challenges, such as regulatory compliance and ensuring the availability of safe and authentic medications, which will require ongoing oversight and consumer education.

By Sales Channel

Prescription-based:

Prescription-based sales remain the predominant channel for distributing rheumatoid arthritis drugs, particularly for more potent medications such as biologics and DMARDs. The need for healthcare provider oversight and monitoring during treatment initiation and throughout the therapeutic journey underscores the importance of this channel. Prescription medications are typically more effective for managing severe cases of RA, necessitating healthcare providers' involvement in determining appropriate treatment plans. Moreover, as new therapies are introduced, healthcare professionals play a critical role in educating patients about the benefits and potential risks associated with these medications. Given the complexity of rheumatoid arthritis and the need for personalized treatment strategies, prescription-based sales are expected to continue dominating the market.

Over-the-counter:

Over-the-counter (OTC) sales of rheumatoid arthritis medications primarily involve the distribution of NSAIDs and topical treatments that can be purchased without a prescription. OTC medications play a vital role in managing mild to moderate symptoms of rheumatoid arthritis, providing patients with accessible options for pain relief. While OTC products are generally less potent than prescription medications, they serve as an essential complement to a comprehensive treatment plan for many patients. The convenience and availability of OTC options are likely to drive their growth in the market, particularly as patients seek immediate solutions for symptom management. Moreover, increasing awareness of arthritis and self-care strategies is expected to further promote the use of OTC medications.

By Region

The North American region dominates the global Rheumatoid Arthritis Drugs market, accounting for over 40% of the total market share. The high incidence of rheumatoid arthritis, coupled with advanced healthcare infrastructure and increased access to novel therapies, contributes to this dominance. The region is also home to numerous pharmaceutical companies actively engaged in the research and development of innovative drugs, further bolstering market growth. The CAGR for the North American market is expected to be approximately 8% during the forecast period, driven by the increasing adoption of biologics and targeted therapies. Furthermore, growing awareness of RA management and the emphasis on personalized medicine are anticipated to contribute positively to market dynamics within this region.

Europe follows North America in terms of market share, accounting for nearly 30% of the global Rheumatoid Arthritis Drugs market. Several European countries have well-established healthcare systems, ensuring access to a wide range of treatment options for patients with rheumatoid arthritis. The growing geriatric population and the rising prevalence of autoimmune diseases are key factors propelling market growth in this region. Moreover, ongoing research and clinical trials in Europe aimed at discovering new therapeutic agents will likely lead to the introduction of novel drugs, enhancing treatment choices for patients. The Asia Pacific region is also expected to witness significant growth, with a CAGR of around 6.5% during the forecast period, driven by increasing awareness, improving healthcare infrastructure, and rising disposable incomes.

Opportunities

The Rheumatoid Arthritis Drugs market presents numerous opportunities for growth, particularly in the realm of research and development. With the ongoing advancements in biotechnology and pharmaceutical sciences, there is a continuous push towards discovering novel therapies, including biologics and JAK inhibitors, that target the underlying mechanisms of rheumatoid arthritis. The increasing investment in clinical trials is expected to facilitate the introduction of new drugs that offer enhanced efficacy and safety profiles. Additionally, the growing trend of personalized medicine is anticipated to reshape treatment approaches, allowing healthcare providers to tailor therapies to individual patient characteristics. This shift can lead to improved patient outcomes and enhanced adherence to treatment protocols, thereby fostering market growth.

Another significant opportunity lies in the expanding patient population seeking effective management for rheumatoid arthritis. As awareness regarding the disease and its treatment options increases, more patients are likely to seek medical advice and pursue treatment, driving demand for effective medications. Furthermore, the rise of telemedicine and digital health solutions provides an innovative platform for enhancing patient engagement and education, leading to better disease management. The integration of technology into healthcare can also facilitate remote monitoring and support for patients, ensuring they receive timely interventions and follow-ups. These developments not only enhance the patient experience but also provide pharmaceutical companies with valuable insights into patient needs, driving innovation in drug development.

Threats

Despite the promising outlook for the Rheumatoid Arthritis Drugs market, several threats could hinder its growth. One of the primary concerns is the potential for drug pricing pressures and reimbursement challenges, particularly in regions with stringent healthcare regulations. The increasing cost of biologics, for instance, can limit access for patients and may lead to treatment discontinuation, adversely affecting patient health outcomes. Additionally, the emergence of generic alternatives may impact the market share of branded products, prompting pharmaceutical companies to strategize on differentiation and market positioning. Moreover, regulatory hurdles and lengthy approval processes for new drugs can delay the introduction of innovative therapies, thereby limiting competition and growth in the market.

Another significant threat comes from the rising prevalence of counterfeit medications, particularly in online pharmacies. The growing trend of purchasing medications online can expose patients to substandard or fraudulent products, posing serious risks to their health. Ensuring the authenticity and safety of medications is critical to maintaining patient trust in the healthcare system. Furthermore, the increasing focus on patient safety and pharmacovigilance may lead to heightened scrutiny of drug side effects and long-term efficacy, potentially impacting the approval and marketability of certain medications. Pharmaceutical companies must navigate these challenges while prioritizing ethical practices and ensuring the delivery of safe and effective treatment options for patients with rheumatoid arthritis.

Competitor Outlook

• AbbVie Inc.
• Amgen Inc.
• Pfizer Inc.
• Johnson & Johnson
• Roche Holding AG
• Merck & Co., Inc.
• Sanofi S.A.
• Novartis AG
• Bristol-Myers Squibb Company
• UCB S.A.
• GlaxoSmithKline plc
• Gilead Sciences, Inc.
• Teva Pharmaceutical Industries Ltd.
• AstraZeneca plc
• Celgene Corporation

The competitive landscape of the Rheumatoid Arthritis Drugs market is characterized by a diverse range of players, including large multinational pharmaceutical companies and smaller biotech firms. Major companies such as AbbVie, Pfizer, and Johnson & Johnson are at the forefront of this market, continuously striving to innovate and expand their product portfolios. These companies invest heavily in research and development to bring new therapies to market while also focusing on strategic collaborations and partnerships to enhance their market presence. The competition is fierce, with companies vying for market share through the introduction of novel therapies, aggressive marketing strategies, and effective management of distribution channels. Additionally, the growing emphasis on personalized medicine has prompted many pharmaceutical companies to explore targeted therapies tailored to individual patient needs.

AbbVie Inc. is a significant player in the Rheumatoid Arthritis Drugs market, renowned for its blockbuster biologic, Humira (adalimumab), which has been a dominant treatment for RA for years. The company's commitment to research and development has resulted in the launch of several innovative therapies, including Rinvoq (upadacitinib), a JAK inhibitor, establishing AbbVie as a leader in the field. Similarly, Amgen Inc. has made its mark with the introduction of Enbrel (etanercept), a widely prescribed biologic for rheumatoid arthritis, and continues to invest in developing new treatment options. Pfizer Inc. is also noteworthy for its extensive portfolio of rheumatoid arthritis drugs, including Xeljanz (tofacitinib), a JAK inhibitor that has gained traction in recent years. The strategic positioning of these companies and their ongoing efforts to enhance treatment options significantly influence the overall competitive landscape of the market.

Other prominent companies, such as Roche Holding AG and Merck & Co., Inc., are also actively engaged in the development of biologics and targeted therapies for rheumatoid arthritis. Roche's Actemra (tocilizumab) and Merck's Keytruda (pembrolizumab) exemplify the innovative approaches these companies are taking to address the unmet needs of RA patients. Furthermore, companies like Gilead Sciences and Bristol-Myers Squibb are exploring novel treatment pathways, focusing on precision medicine and biologic therapies. The competitive landscape is further augmented by the presence of emerging players and smaller biotech firms, which contribute to a dynamic environment where innovation is paramount. As research continues and new therapies are developed, the competitive landscape will likely evolve, fostering ongoing advancements in the management of rheumatoid arthritis.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 UCB S.A.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Amgen Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 AstraZeneca plc
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Roche Holding AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Johnson & Johnson
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Merck & Co., Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Celgene Corporation
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 GlaxoSmithKline plc
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Gilead Sciences, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Bristol-Myers Squibb Company
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Rheumatoid Arthritis Drugs Market, By Drug Type
    • 6.1.1 Nonsteroidal Anti-Inflammatory Drugs
    • 6.1.2 Corticosteroids
    • 6.1.3 Disease-Modifying Antirheumatic Drugs
    • 6.1.4 Biologics
    • 6.1.5 Janus Kinase Inhibitors
  • 6.2 Rheumatoid Arthritis Drugs Market, By Sales Channel
    • 6.2.1 Prescription-based
    • 6.2.2 Over-the-counter
  • 6.3 Rheumatoid Arthritis Drugs Market, By Distribution Channel
    • 6.3.1 Hospital Pharmacies
    • 6.3.2 Retail Pharmacies
    • 6.3.3 Online Pharmacies
  • 6.4 Rheumatoid Arthritis Drugs Market, By Route of Administration
    • 6.4.1 Oral
    • 6.4.2 Parenteral
    • 6.4.3 Topical

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Rheumatoid Arthritis Drugs Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Rheumatoid Arthritis Drugs market is categorized based on

By Drug Type

• Nonsteroidal Anti-Inflammatory Drugs
• Corticosteroids
• Disease-Modifying Antirheumatic Drugs
• Biologics
• Janus Kinase Inhibitors

By Route of Administration

• Oral
• Parenteral
• Topical

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Sales Channel

• Prescription-based
• Over-the-counter

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• AbbVie Inc.
• Amgen Inc.
• Pfizer Inc.
• Johnson & Johnson
• Roche Holding AG
• Merck & Co., Inc.
• Sanofi S.A.
• Novartis AG
• Bristol-Myers Squibb Company
• UCB S.A.
• GlaxoSmithKline plc
• Gilead Sciences, Inc.
• Teva Pharmaceutical Industries Ltd.
• AstraZeneca plc
• Celgene Corporation